Device Trial Radar · NCT07941167
Gapless ECG-Monitoring for Stroke Prevention by Atrial Fibrillation Detection (GEMS-PAF-randomized Trial) - A Multi-centre, Randomized Controlled Outcome Trial.
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
442
Planned (sponsor's estimate)
Start
Nov 20, 2026
Primary completion
Nov 20, 2029
Study completion Nov 20, 2029
Sponsor
- Lead sponsor
- Medical University of ViennaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Abbott; VASCage GmbH
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. What is the purpose of this clinical trial? All of the participants in this trial have been diagnosed with a stroke or transitoric ischaemic attack within 72 hours of inclusion. Strokes are usually caused by a blood clot, which subsequently leads to a blockage of a blood vessel in the brain. In more than 20% of patients who have had a stroke or a transient ischemic attack (TIA, a temporary reduction in blood flow to the brain), atrial fibrillation (AF) is detectable on the electrocardiogram (ECG) as a possible cause. AF is a cardiac arrhythmia characterized by irregular activity in the atria, affecting a total of 1-2% of the population. This means that approximately 100,000 people in Austria are affected. AF is also an age-related cardiac arrhythmia, so that its prevalence is already 6% among people over 65 and up to 20% among those over 80. The risk of a recurrent stroke is five times higher in patients with AF; however, this risk can be significantly reduced through the use of blood-thinning medications. However, many patients suffer from "silent" atrial fibrillation-which they themselves do not notice-that may go undetected using standard monitoring methods in the hospital or, later, on an outpatient basis. Standard monitoring methods consist of a resting electrocardiogram (ECG) upon admission to the hospital, the ECG recorded during the first few days of hospitalization in the stroke unit, and usually also a long-term ECG (Holter ECG monitoring, typically over 24 hours) performed as part of further inpatient treatment; the latter can be repeated on an outpatient basis after discharge. These measures can improve the detection rate of AF. One problem, however, is that time gaps arise between the individual monitoring steps, which means that a AF episode may go unnoticed. Since 2016, international treatment guidelines have also recommended extended, continuous ECG monitoring. One option available for this purpose is the implantable loop recorder (ILR), which is implanted under the skin and continuously records an ECG (loop = without interruption) for 3-5 years. The goal of this study is to investigate whether the early implantation of a loop recorder-already in the stroke unit-can detect atrial fibrillation to a greater extent than conventional, routine standard monitoring, and thereby prevent the occurrence of a recurrent stroke within one year. For this, it is necessary that 1) two groups be formed through random assignment and 2) a control magnetic resonance imaging (MRI) scan of the skull be performed after 12 months to detect even "silent" strokes. 2. How does the clinical trial work, what is an implantable loop recorder, and how is it implanted? The trial is being conducted at several hospitals in Austria. The departments leading the trial at the AKH are the Departments of Cardiology and Neurology. The aim of the study is to determine whether continuous ECG monitoring, initiated early-shortly after the stroke-can detect sudden-onset atrial fibrillation more frequently or earlier than a routine monitoring regimen used in everyday clinical practice. Half of all patients enrolled in the study will have a loop recorder implanted while they are still in the stroke unit, within the first 5 days after the stroke. The loop recorder is an established standard of care. This decision is made randomly (2 groups). The loop recorder is usually implanted on the left side of the chest during a minor surgical procedure. At this site, the doctor makes a small incision (approximately 1 cm long) under local anesthesia, through which the loop recorder is inserted directly under the skin. The incision is closed with sterile adhesive strips (rarely with a suture). A commercially available loop recorder from Abbott®, which has been used for this indication for several years, will be used-specifically, the "Assert-IQ" model. The loop recorder transmits events recorded daily to a network via the cellular network. Within this network, the physician can access patient data and take action as needed. The procedure typically takes only a few minutes and is minimally invasive. The loop recorder is used only for recording and documenting, not for treating cardiac arrhythmias. Once the wound has healed, malfunctions of the device are rare. However, external factors (e.g., electrical devices) can cause the loop recorder to malfunction. More frequent detection of atrial fibrillation is expected as a result of more intensive ECG monitoring using an implantable loop recorder (ILR). In patients with AF following a stroke, oral anticoagulation with Marcumar or a related medication is associated with a significant reduction in the risk of recurrent strokes. We anticipate that, as a result, a larger proportion of patients will be treated with oral anticoagulants, which will in turn reduce the risk of recurrent strokes.
Conditions
- Ischaemic Stroke
- TIA (Transient Ischemic Attack)
- Atrial Fibrillation (Paroxysmal)
- Stroke Recurrence
- Stroke Ischemic
- Stroke (CVA) or TIA
- Stroke (CVA) or Transient Ischemic Attack
- Stroke (in Patients With Atrial Fibrillation)
- Stroke Acute
- Atrial Fibrillation (AF)
- Atrial Fibrillation (Prevention of Stroke)
- Cryptogenic Stroke
Interventions
Ultra-early Implantable loop recorder (ILR) implantationDevice
The implantable loop recorder (ILR) that is going to be used is the Abbott Assert IQ of Abbott´s insertable cardiac monitor system (ICM) with remote monitoring. Implantation will occur during stroke unit stay, no more than 5 days after the index event (Stroke/TIA). ECG-monitoring is gapless. Assert IQ ICM is an insertable automatically activated and patient- activated monitoring system that records subcutaneous ECG and is indicated in the following cases: * Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias * Patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia Patients can use their smartphone to automatically transfer device data via a mobile App. Smart memory management eliminates the need for manual transmissions. The ILR will stay implanted until battery depletion or if the diagnosis and therapy will not demand any further prolonged monitoring.
Conventional stroke unit care ECG-monitoringOther
Conventional stroke unit care ECG-monitoring includes continuous standard ECG-monitoring in the first days after the index event (Stroke/TIA). Additionally at least one 24-72h-Holter ECG will be performed during hospital admission and/or after discharge in the ambulatory setting according to the post-stroke follow-up protocols of the treating stroke center.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stroke recurrenceTime frame: From enrollment to the final study concluding MRI a time period of 12 months is planned.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien (AKH)
Vienna, State of Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.